MarketCap
Facebook
X
Telegram
STAAR Surgical Company Financial Ratios 2026-2009 | STAA
Brief overview of STAAR Surgical Company's valuation and returns
The review covers five available annual periods spanning 2018 to 2023.
The valuation comparison uses P/E 74.65x (median 112.3x), EV/EBITDA 45.57x (median 88.96x), P/S 3.93x (median 4.94x). Multiples are on average 33.5% below their own medians. Shares look cheaper than their recent historical valuation.
Current earnings relative to valuation equal about 1.3% on the 1/P/E measure. This is a valuation reference, not an expected payout.
End-period return metrics are ROE -23.4%, ROA -17.8%, ROCE -26.6%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
On PEG (0.65x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
The cash conversion cycle is 1.1 days versus 0 days initially. Turnover changed little.
Conclusion
STAAR Surgical Company's discount may reflect genuine profitability issues rather than market inefficiency alone.
Annual Financial Ratios STAAR Surgical Company
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-11.7 | -41.2 | 74.6 | 39.7 | 124.8 | 112.3 | - | 325.1 | -315.3 | -39.2 | -27.2 | 1584.5 | - | -105.9 | 320.2 | 3.4 | - |
P/S |
3.9 | 2.6 | 4.9 | 6.6 | 14.9 | 10.5 | - | 13.0 | 7.4 | 3.3 | 3.0 | 8.8 | - | 3.0 | 6.6 | - | - |
EPS |
-1.6 | -0.4 | 0.4 | 0.8 | 0.6 | 0.3 | - | 0.1 | -0.1 | -0.3 | -0.2 | 0.0 | - | -0.1 | 0.0 | - | - |
EV (Enterprise Value) |
895 M | 800 M | 1.51 B | 1.57 B | 3.32 B | 1.5 B | - | 1.55 B | 684 M | 266 M | 237 M | 634 M | - | 192 M | 419 M | 8.96 M | -6.33 M |
EBITDA per Share |
-1.68 | -0.12 | 0.68 | 1.01 | 0.78 | 0.332 | - | 0.2 | -0.00676 | -0.0748 | -0.146 | 0.0738 | - | 0.0209 | 0.137 | -29.1 | - |
EV/EBITDA |
-10.7 | -139.8 | 45.6 | 32.6 | 89.0 | 93.9 | - | 167.3 | -2386.2 | -84.2 | -39.5 | 216.0 | - | 230.6 | 79.6 | -8.9 | - |
PEG |
- | - | - | - | - | 0.65 | - | 1.05 | -3.82 | -1.6 | 0.01 | 13.11 | - | 0.44 | 0.14 | - | - |
P/B |
2.7 | 2.1 | 4.1 | 4.7 | 13.3 | 9.9 | - | 12.2 | 15.7 | 6.6 | 6.2 | 16.3 | - | 6.0 | 14.1 | 0.0 | - |
P/CF |
-27.5 | 52.9 | 109.2 | 44.1 | 78.1 | 101.0 | - | 153.5 | 373.3 | -60.9 | -19.0 | -7042.4 | - | 200.6 | 94.8 | -0.0 | - |
ROE % |
-23.37 | -5.09 | 5.53 | 11.80 | 10.52 | 8.79 | - | 3.75 | -4.98 | -16.82 | -22.62 | 1.03 | - | -5.68 | 4.41 | 0.24 | - |
ROA % |
-17.81 | -3.97 | 4.37 | 9.47 | 7.96 | 6.79 | - | 2.97 | -3.03 | -10.38 | -14.25 | 0.65 | - | -3.28 | 2.65 | 0.13 | - |
ROCE % |
-26.65 | -3.17 | 7.28 | 13.03 | 12.75 | 6.88 | - | 4.72 | -7.43 | -11.84 | -18.87 | 1.61 | - | -3.25 | 8.00 | -11.60 | - |
Current Ratio |
4.2 | 4.5 | 4.8 | 5.1 | 4.0 | 5.1 | - | 5.5 | 2.6 | 2.7 | 2.7 | 2.7 | - | 2.5 | 2.8 | 2.2 | - |
DSO |
38.2 | 100.3 | 89.0 | 80.8 | 59.0 | 79.5 | - | 81.6 | 86.6 | 80.4 | 57.3 | 57.1 | - | 50.9 | 54.6 | - | - |
DIO |
- | - | - | - | - | 163.7 | - | 187.9 | 189.5 | 238.2 | 219.3 | 208.3 | - | 219.0 | 195.0 | 96.8 | - |
DPO |
37.0 | 74.3 | 65.7 | 60.7 | 59.0 | 76.9 | - | 73.4 | 83.6 | 100.1 | 92.4 | 105.0 | - | 95.5 | 76.9 | 34.1 | - |
Operating Cycle |
38.2 | 100.3 | 89.0 | 80.8 | 59.0 | 243.2 | - | 269.5 | 276.1 | 318.6 | 276.6 | 265.5 | - | 269.9 | 249.7 | 96.8 | - |
Cash Conversion Cycle |
1.1 | 26.0 | 23.2 | 20.1 | 0.0 | 166.3 | - | 196.1 | 192.5 | 218.5 | 184.2 | 160.5 | - | 174.5 | 172.7 | 62.7 | - |
All numbers in USD currency
Quarterly Financial Ratios STAAR Surgical Company
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.1 | 0.18 | -0.34 | -1.1 | - | 0.2 | 0.15 | -0.07 | - | 0.1 | 0.13 | 0.06 | - | 0.21 | 0.27 | 0.2 | 0.1 | 0.13 | 0.18 | 0.11 | 0.14 | 0.08 | -0.03 | - | - | 0.05 | 0.09 | 0.03 | 0.02 | 0.03 | 0.04 | 0.01 | - | 0.03 | -0.02 | -0.05 | - | -0.04 | -0.05 | -0.2 | -0.07 | -0.04 | -0.04 | -0.06 | -0.02 | -0.07 | -0.05 | -0.04 | - | 0.01 | 0.01 | 0.01 | -0.04 | - | -0.01 | 0.01 | - | - | 0.02 | 0.01 |
EBITDA per Share |
0.2 | - | - | -1.12 | - | - | - | -0.02 | - | - | - | 0.08 | - | 0.35 | 0.4 | 0.27 | - | 0.22 | 0.26 | 0.18 | - | 0.16 | 0.01 | -0.01 | - | 0.14 | 0.15 | 0.06 | - | 0.08 | 0.1 | 0.03 | - | 0.08 | 0.01 | -0.03 | - | 0.01 | -0.02 | -0.24 | - | -0.01 | -0.02 | -0.03 | - | - | -0.01 | -0.02 | - | 0.04 | 0.04 | 0.04 | - | 0.02 | 0.01 | 0.02 | - | 0.05 | 0.05 | 0.01 |
ROE % |
-16.50 | -15.64 | -16.35 | -12.21 | 3.28 | 4.56 | 3.92 | 2.91 | 3.76 | 6.93 | 10.02 | 11.80 | 11.01 | 12.91 | 12.15 | 11.45 | 10.30 | 12.39 | 12.06 | 7.74 | 5.33 | 2.93 | 3.56 | 5.22 | 5.31 | 6.13 | 5.64 | 4.31 | 3.75 | 2.60 | 4.23 | 0.59 | -4.98 | -5.10 | -12.52 | -15.92 | -32.00 | -38.40 | -38.14 | -36.50 | -21.73 | -17.14 | -19.37 | -19.63 | -16.48 | -12.84 | -5.38 | 0.34 | 3.63 | -0.82 | -2.49 | -4.84 | -5.55 | -0.73 | -0.18 | 4.29 | 4.57 | 0.26 | 2.92 | 1.02 |
ROA % |
-12.59 | -11.89 | -12.40 | -9.24 | 2.62 | 3.64 | 3.16 | 2.37 | 3.04 | 5.64 | 8.09 | 9.45 | 8.80 | 10.23 | 9.48 | 8.92 | 8.07 | 9.72 | 9.52 | 6.07 | 4.13 | 2.29 | 2.74 | 4.05 | 4.12 | 4.77 | 4.40 | 3.39 | 2.97 | 2.11 | 2.90 | 0.43 | -3.04 | -3.09 | -7.48 | -9.37 | -18.53 | -22.59 | -22.70 | -22.08 | -13.91 | -11.02 | -12.49 | -12.62 | -10.62 | -8.32 | -3.50 | 0.17 | 2.28 | -0.30 | -1.34 | -2.75 | -3.22 | -0.41 | -0.09 | 2.56 | 2.75 | 0.16 | 1.76 | 0.61 |
ROCE % |
-17.81 | -18.75 | -21.07 | -12.75 | 3.65 | 5.32 | 6.39 | 4.30 | 4.88 | 9.12 | 13.15 | 15.13 | 14.31 | 17.46 | 17.76 | 15.56 | 11.17 | 13.79 | 10.04 | 4.81 | 1.33 | 3.56 | 4.14 | 5.88 | 6.57 | 7.76 | 7.81 | 5.22 | 4.08 | 6.52 | 2.25 | -4.89 | -5.50 | -10.02 | -18.10 | -41.55 | -36.70 | -41.81 | -41.67 | -40.17 | -13.65 | -17.47 | -15.68 | -14.55 | -10.40 | -9.94 | -4.12 | 2.53 | 5.78 | 5.49 | 4.52 | 3.39 | 0.07 | 2.57 | 6.83 | 8.06 | 7.18 | 2.50 | 3.97 | 0.71 |
Current Ratio |
4.6 | 4.5 | 4.3 | 4.3 | 4.5 | 4.9 | 5.0 | 4.9 | 4.8 | 5.1 | 5.1 | 5.2 | 5.1 | 5.3 | 4.9 | 4.7 | 4.0 | 4.3 | 4.9 | 5.2 | 4.4 | 4.9 | 5.0 | 4.9 | - | 4.4 | 4.5 | 4.4 | 4.8 | 4.8 | 4.8 | 4.8 | 2.7 | 2.6 | 2.6 | 2.6 | 2.4 | 2.4 | 2.4 | 2.4 | 2.7 | 2.8 | 2.9 | 2.8 | 2.7 | 2.8 | 2.9 | 2.8 | - | 2.7 | 2.7 | 2.6 | 2.4 | 2.4 | 2.4 | 2.4 | 2.5 | 2.5 | 2.5 | 2.5 |
DSO |
68.9 | 45.5 | 76.6 | 126.2 | - | 102.1 | 73.0 | 94.0 | - | 117.5 | 78.1 | 78.2 | - | 70.9 | 61.8 | 65.4 | 66.1 | 70.8 | 60.3 | 58.2 | 85.7 | 79.0 | 95.9 | 44.7 | - | 74.5 | 68.5 | 73.6 | 75.9 | 74.5 | 69.8 | 73.8 | 69.6 | 77.9 | 83.3 | 80.1 | 66.0 | 74.4 | 71.1 | 64.9 | 65.6 | 61.5 | 57.5 | 52.7 | 53.9 | 61.1 | 54.2 | 25.1 | - | 52.8 | 47.6 | 43.5 | 47.3 | 49.1 | 48.9 | 51.9 | 50.6 | 54.3 | 51.0 | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 125.8 | - | - | - | 114.3 | - | 220.6 | 213.2 | 212.8 | - | 221.4 | 205.3 | 99.9 | - | 207.9 | 182.2 | 193.6 | - | 227.1 | 217.5 | 223.9 | - | 207.2 | 184.5 | - |
DPO |
33.1 | 58.3 | 94.3 | 88.1 | - | 76.6 | 78.9 | 84.2 | - | 55.4 | 43.4 | 59.1 | - | 59.4 | 69.2 | 72.4 | - | 58.3 | 53.4 | 62.4 | - | 62.5 | 78.0 | 41.6 | - | 71.3 | 70.6 | 73.5 | - | 75.3 | 68.6 | 74.8 | - | 83.1 | 85.2 | 113.4 | - | 146.4 | 119.5 | 108.5 | - | 80.9 | 70.3 | 85.8 | - | 83.2 | 81.7 | 44.7 | - | 75.4 | 61.5 | 75.0 | - | 99.8 | 95.6 | 93.0 | - | 80.7 | 71.9 | - |
Operating Cycle |
- | 45.5 | 76.6 | 126.2 | - | 102.1 | 73.0 | 94.0 | - | 117.5 | 78.1 | 78.2 | - | 70.9 | 61.8 | 65.4 | 66.1 | 70.8 | 60.3 | 58.2 | 85.7 | 79.0 | 95.9 | 44.7 | - | 74.5 | 68.5 | 73.6 | 75.9 | 74.5 | 69.8 | 73.8 | 69.6 | 77.9 | 83.3 | 205.9 | 66.0 | 74.4 | 71.1 | 179.1 | 65.6 | 282.1 | 270.7 | 265.4 | 53.9 | 282.5 | 259.5 | 125.0 | - | 260.8 | 229.8 | 237.0 | 47.3 | 276.2 | 266.4 | 275.8 | 50.6 | 261.5 | 235.4 | - |
Cash Conversion Cycle |
- | -12.7 | -17.7 | 38.1 | - | 25.5 | -5.9 | 9.8 | - | 62.1 | 34.6 | 19.1 | - | 11.6 | -7.4 | -7.0 | 66.1 | 12.5 | 6.8 | -4.2 | 85.7 | 16.5 | 17.9 | 3.1 | - | 3.2 | -2.1 | 0.1 | 75.9 | -0.7 | 1.2 | -1.0 | 69.6 | -5.2 | -1.9 | 92.5 | 66.0 | -72.0 | -48.4 | 70.6 | 65.6 | 201.2 | 200.4 | 179.6 | 53.9 | 199.3 | 177.8 | 80.4 | - | 185.3 | 168.3 | 162.0 | 47.3 | 176.4 | 170.8 | 182.8 | 50.6 | 180.8 | 163.6 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company STAAR Surgical Company, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Schweiz
Israel
